PLOS
open access
CC BY
Real-world effectiveness of Paxlovid in protecting Long COVID for outpatient adult patients: A target trial emulation study from the RECOVER Initiative
Paxlovid (nirmatrelvir/ritonavir) has been approved for use in patients who are at high risk for severe acute COVID-19 illness. Evidence regarding whether acute use of Paxlovid protects against Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or Long COVID, is mixed in high-risk patients and lac
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease#912234
- Prophylaxis and Treatment of COVID-19#1186000
- Oral nirmatrelvir-ritonavir for COVID-19 in higher risk outpatients#298976
- Nirmatrelvir–ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial#1424936
- Nirmatrelvir-Ritonavir Targeting Viral Persistence in Post-COVID-19 Condition (Long Covid) in the USA (RECOVER-VITAL): A Randomized, Double-Blind, Placebo Controlled, Phase 2 Trial#1404561
Record · ID 1481117
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive